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gene therapyAs recently demonstrated in patients with factor IX deﬁciency, adeno‐associated virus (AAV)-mediated liver-
directed therapy is a viable option for inherited metabolic liver disorders. Our aim is to treat Crigler-Najjar
syndrome type I (CN I), an inherited severe unconjugated hyperbilirubinemia, as a rare recessive inherited
disorder. Because the number of patients eligible for this approach is small, the efﬁcacy can only be demon-
strated by a beneﬁcial effect on the pathophysiology in individual patients. Serum bilirubin levels in potential
candidates have been monitored since birth, providing an indication of their pathophysiology. Adjuvant pho-
totherapy to prevent brain damage reduces serum unconjugated bilirubin (UCB) levels in CN I patients to the
level seen in the milder form of the disease, CN type II. This therapy increases the excretion of UCB, thereby
complicating the use of UCB and conjugated bilirubin levels in serum as biomarkers for the gene therapy we
try to develop. Therefore, a suitable biomarker that is not affected by phototherapy is currently needed. To
this end, we have investigated whether estradiol, ethinylestradiol or ezetimibe could be used as markers
for uridine 5'-di-phospho-glucuronosyltransferase isoform 1A1 (UGT1A1) activity restored by AAV gene
therapy in Gunn rats, a relevant animal model for CN I. Of these compounds, ezetimibe appeared most suit-
able because its glucuronidation rate in untreated control Gunn rats is low. Subsequently, ezetimibe
glucuronidation was studied in both untreated and AAV-treated Gunn rats and the results suggest that it
may serve as a useful serum marker for restored hepatic UGT1A1 activity.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Liver-directed gene therapy has recently been demonstrated to be
a viable option for the treatment of inherited liver disorders. Systemic
injection of a self complementary adeno‐associated viral vector
(scAAV) not only appeared safe but also provided effective correction
of hepatic factor IX synthesis in hemophilia B patients [1]. When
considering the shortage of donor organs and the adverse effects of
long-term immune suppression, gene therapy seems a preferable
alternative for liver transplantation. Our long‐term goal is to use
this approach to restore hepatic UGT1A1 activity for treating
Crigler-Najjar syndrome type I (CN I, OMIM ID: 218800), an inheritedbilirubin mono-glucuronide;
rus; scAAV, self complementa-
igler-Najjar syndrome type II;
isoform 1A1; UDPGA, uridine
iol; E2, 17β-estradiol
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rights reserved.severe unconjugated hyperbilirubinemia [2–4]. In a relevant animal
model for this disease, the Gunn rat, a single injection of AAV vector
that ferry the human UGT1A1 gene (GENBANK ID: NM_000463.2)
to the liver provided life-long correction of serum bilirubin levels
[5]. The proof of concept in this preclinical model and the efﬁcacy
reported for scAAV‐mediated gene therapy in hemophilia B patients
strongly support the development of a phase 1 trial in CN I patients.
CN I, like other recessively inherited metabolic liver disorders, is a
very rare syndrome. The limited number of patients does not allow a
comparison between treated and untreated patients to demonstrate
clinical efﬁcacy. Instead, characterization of the pathophysiology in
each patient pre- and posttreatment needs to be performed to establish
efﬁcacy. For factor IX, an excreted protein, efﬁcacy was demonstrated
by showing a signiﬁcant increase in its serum levels that normalized
blood clotting time or reduced the need for factor IX injections [1,6].
For intracellular metabolic enzymes, such as UGT1A1, efﬁcacy can
only be demonstrated by a signiﬁcant effect on the relevant activ-
ity and metabolic pathway. In the case of UGT1A1, this means a
signiﬁcant reduction of serum unconjugated bilirubin (UCB) levels
upon treatment.
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since it is essential to prevent irreversible brain damage [7,8] and
should not be halted. This, however, complicates the establishment
of pretreatment levels of UCB. Phototherapy is a cumbersome treat-
ment that has a major impact on the patients’ life quality since it re-
quires a daily whole body exposure to blue light for 8–12 h.
Therefore, the clinical aim of gene therapy treatment is to overcome
the need for phototherapy, even if complete normalization of serum
bilirubin is not expected and is not essential (it is not reached by pho-
totherapy, either). Most patients with the milder form of the disease,
CN type II (OMIM ID: 606785), reach adulthood in good health with-
out treatment while having serum UCB levels around 300 μM [4,9]. It
is thus expected that a gene therapy treatment that restores hepatic
UGT1A1 activity to the low level in CN II patients will provide thera-
peutic efﬁcacy in CN I patients.
Since phototherapy for CN I patients should not be stopped even if
it hampers the use of serum bilirubin as a biomarker for gene therapy
development, it is important to ﬁnd another suitable biomarker that
is not, or much less, affected by phototherapy but still provides a
good method to evaluate the gene therapy efﬁcacy, a biomarker
that is sensitive enough to show an increase in hepatic UGT1A1 activ-
ity to the low activity in CN II patients. One option seemed to be the
presence of bilirubin glucuronides in bile [10]. To establish the suit-
ability of this parameter, the correlation between bilirubin glucuro-
nides in bile and the need for phototherapy was determined in 16
CN patients in the Netherlands. In addition, the correlation between
bilirubin glucuronide (BDG) in bile and serum bilirubin levels was de-
termined in these patients, as well as in a large number of Gunn rats
upon treatment with scAAV. The results did not demonstrate such a
correlation in the patients, however, most likely because it is not in-
dependent of phototherapy that increases the excretion of UCB to
bile [11–13].
Since bile analysis requires an invasive endoscopy, a speciﬁc non-
toxic UGT1A1 substrate that could be used as a serum marker would
be preferable for efﬁcacy demonstration. The ﬁrst challenge one en-
counters in trying to identify such a compound (that is not bilirubin)
is the large partial overlap in substrate speciﬁcity between UGT1A1
and other UGT enzymes. The number of potential compounds that
may be useful as speciﬁc UGT1A1 activity indicators is limited and
not all of them can serve as suitable biomarkers. For this study we
have selected three nontoxic compounds that are partly or fully spe-
ciﬁc UGT1A1 substrates, namely estradiol, ethinylestradiol and
ezetimibe [14–16] and examined their suitability as a potential
serum biomarker for UGT1A1 activity. The results suggest that in
the Gunn rat experimental system, ezetimibe may be a suitableTable 1
Data about the CN I and CN II patients that were included in this study. The information con
gender, average serum bilirubin levels and the relative amounts of unconjugated bilirubin,
plantation; #, levels prior to OLT;*, suffered from transient bilirubin toxicity.
Pt's CN type Protein protein Daily phototherapy
1 I Q49X 1085-2A->G >10 h
2 I Y74X K407X >10 h
3 I K407X K407X 10 h
4 I K407X K407X 10–12 h
5 I K407X K407X 10–14 h
6 I K407X K407X 10 h
7 I K402T K402T 10 h
8 II L15R L15R 2 h
9 II L15R K407X 3 h
10 II L15R S190F
11 II G71R K407X
12 II G71R K407X
13 II R336W p.A498PfsX3 b3 h
14 II R336W p.A498PfsX3 b3 h
15 II L15R L15R 2×30 min
16 II L443P L443Pbiomarker for the development of a gene therapy treatment to im-
prove the health and life quality of CN I patients.
2. Material and methods
Bilirubin, 17β-estradiol (E2), 17α-ethinylestradiol (EED), uridine
5'-diphosphoglucuronic acid triammonium salt (UDPGA), and
alamethicin were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Ezetimibe for in vitro testing was from Kemprotec Ltd.
(Middlesbrough, UK) and for in vivo testing fromMSD (Hertfordshire,
UK).
3. Patients
All patient studies were performed according to the Helsinki dec-
laration and with the permission of the Medical Ethical Committee.
Seven CN I patients and nine CN II patients were investigated. Most
of them were under our surveillance since birth, but patients 14, 15
and 16 came under our control at a later age. The phenobarbital re-
sponse was tested by oral administration of 7 mg/kg/day, as part of
the standard care and was performed in most patients during the
ﬁrst year of life in order to differentiate CN I from CN II. All CN muta-
tions in these patients have been reported previously [17]. An over-
view of the phototherapy applied in these patients and the
mutations identiﬁed in them is given in (Table 1). Bile sampling and
analysis was performed as reported earlier [10]
4. Animal experiments
All animal experiments were performed in accordance with the
animal ethical committee guidelines of the Academic Medical Center
of Amsterdam. Gunn rats from our own colony, 8–10 weeks of age,
with weight between 180 and 200 g for males or 120 and 150 g for fe-
males, were fed ad libitum and randomly assigned to different treat-
ment groups. Rats received an intra portal venous injection of
scAAV2/8-LP1-UGT1A1 that provides expression of human UGT1A1
in liver as described previously [18]. Ezetimibe (20 mg/ml DMSO)
was injected i.p. Blood was sampled in heparin tubes and centrifuged
for 1 min at 10,000 ×g to obtain plasma. Ezetimibe and its glucuro-
nide were extracted and quantiﬁed as previously described [19].
5. Bilirubin quantiﬁcation
Total serum bilirubin was determined by the routine clinical chem-
istry department using a standard colorimetric assay at the departmenttains the UGT1A1 mutation identiﬁed in them, the extent of daily phototherapy, their
as well as the mono- and di-glucuronidated bilirubin in bile. OLT, Orthotop liver trans-
Remarks Sex Serum bilirubin Bile composition
% UCB / BMG / BDG
OLT M 315# 93 / 7 / 0
OLT F 270# 75 / 25 / 0
F 260 95 / 4 / 1
F 235 99 / 1 / 0
M 395 98 / 2 / 0
M 290 97 / 3 / 1
M 295 99 /1 / 0
F 260 41 / 49/ 10
M 370 38 / 50 / 12
F 255 19 / 73 / 8
M 120 16 / 67 / 17
F 181 1 / 86 / 13
OLT M 321# 9 / 86 / 5
* M 410 7 / 86 / 8
M 260 59 / 27 / 14
M 34 / 32 / 34
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gates in bile were quantiﬁed by HPLC using a Pursuit C18, 5 μm, 10 cm
HPLC column (Varian, The Netherlands) as described [5].6. Quantiﬁcation of UGT1A1 activity in Gunn rat liver microsomes
Microsomes were isolated from total liver as described previously
[5]. The glucuronidation activity assay samples contained 50 mM
phosphate buffer pH 7.4, 10 mM MgCl2, 5–50 μg rat microsomes, 5%
alamethicin and aglycone substrate (1 μM ezetimibe or 100 μM EED
or 100 μME2 or 150 μMbilirubin) in a total volume of 100 μl. The sub-
strates were dissolved in either 50% (ezetimibe) or 100% (other sub-
strates) dimethyl sulfoxide (DMSO) before adding them to the
reaction mixtures. The ﬁnal DMSO concentration was 5% or 10%, re-
spectively. The UDPGA concentration was 1 mM in the ezetimibe as-
says and 5 mM in all the other assays. The reactions were initiated
by the addition of UDPGA, then incubated 60 min at 37 °C (15 min
for E2), and ﬁnally terminated with the addition of 100 μl MeOH (bil-
irubin) or 10 μl ice-cold 4 M perchloric acid (other substrates) and
transfer to ice for 10 min. The proteins were sedimented by centrifu-
gation at 16100 g and the supernatants were analyzed by HPLC on a
Shimadzu LC-10 model (Shimadzu Corporation, Kyoto, Japan).
Bilirubin, estradiol and ethinylestradiol glucuronides were sepa-
rated and quantiﬁed as previously described [17,20,21]. Ezetimibe
glucuronides were separated using a Chromolith SpeedROD rp-18e
50×4.6 mm column (Merck, Darmstadt) at 30 °C. The ﬂow rate was
1.6 ml/min and the total run time of this isocratic chromatography
was 16 min. The mobile phase was 70% of 0.1% formic acid in water
and 30% acetonitrile. Glucuronides and unconjugated ezetimibe were
detected by a UV detector at 245 nm. Their relative retention times
were 3.1 min (phenolic glucuronide), 3.7 min (aliphatic glucuronide,
not detected in our assays) and 13.4 min for unconjugated ezetimibe.0
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Fig. 1. Serum bilirubin levels in Crigler-Najjar type I and type II patients. (A) Serum bili-
rubin levels in individual male (♦, ▲) and female (□, ◊, ○) patients with CN I. (B) Serum
bilirubin levels of individual male (♦, ▲, ■, ●) and female (◊, △) patients with CN II.In the absence of authentic ezetimibe glucuronides, quantiﬁcation of
the detected phenolic ezetimibe glucuronide was done using a stan-
dard curve that was generated with unconjugated ezetimibe. In the in
vivo glucuronidation experiments, the separation and quantiﬁcation
of ezetimibe and ezetimibe glucuronide were performed as previously
described, using a BDS Hypersil C18, 3 μm, 15 cm HPLC column [22]. At
the start of the chromatography, the mobile phase was 10% acetoni-
trile/90% ammonium formate (20 mM; pH 3.5), followed after
0.5 min by a linear gradient to 80% acetonitrile in this buffer. The
relative retention times were 12.2 min (phenolic glucuronide) and
17.2 min for unconjugated ezetimibe. Glucuronides and unconjugated
ezetimibe were detected with UV detector at 245 nm and quantiﬁca-
tion using a standard curve.
7. Results
7.1. Serum bilirubin levels in CN I and CN II patients
All CN I patients, as well as CN II patients with a severe phenotype,
have been treated daily by whole body exposure to phototherapy. ToFig. 2. Correlations between bile bilirubin di-glucuronide percentage and serum biliru-
bin concentrations in individual Crigler-Najjar patients (A) and in individual scAAV
treated Gunn rats (B). U, untreated control Gunn rats; L, low dose of scAAV; M, medium
dose of scAAV; H, high dose of scAAV.
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surveillance that, especially, includes regular monitoring of serum bil-
irubin levels. The aim of this intensive treatment is to keep their
serum bilirubin levels below 400 μM, a goal that was accomplished
in themajority of these patients (Fig. 1). This treatment, however, sig-
niﬁcantly affects the quality of life of the patients.
7.2. Correlation of bilirubin glucuronides in bile and serum bilirubin level
in CN patients
The percentage of bilirubin glucuronides in the bile of CN I pa-
tients was below 25% of the total bilirubin (Table 1). All these patients
have been treated for at least 7 h a day with intensive phototherapy.
In CN II patients, in comparison to CN I patients, the UCB levels were
signiﬁcantly lower (pb0.0001) while the BDG levels were signiﬁcant-
ly higher (pb0.01) (Table 1). The highest UCB percentage was 41 in
CN II patients vs. 75% in CN I patients. Nevertheless, in this group
there was no clear distinction between the UCB levels in the CN II pa-
tients that needed phototherapy to those that were safe without it.
Although it seems that patients with less than 30% UCB in bile do
not need phototherapy, two CN II patients needed daily phototherapy
while having bile UCB levels below 10%. With most CN I patients, the
amount of bilirubin mono-glucuronide (BMG) was very low, but in
two patients it reached 25% of all bilirubin. The lowest level of BMG
in CN II patients, 27%, was almost the same as the highest level seen
in a CN I patient. Based on this, the level of bilirubin di-glucuronide
(BDG) seems to be a better indicator for UGT1A1 activity than BMG.
BDG was virtually absent in all CN I patients, while present in all CN
II patients (Table 1). However, the presence of BDG does not clearly
differentiates between patients that need phototherapy to those
that can manage without it. Phototherapy enhances the excretion of
UCB from serum into bile and, thus, leads to the lack of correlation be-
tween bilirubin glucuronides in bile and serum bilirubin levels
(Fig. 2A). If all the patients that are treated with phototherapy were
left out of the comparison of serum bilirubin levels and bilirubin glu-
curonide in bile, the correlation in the four remaining patients would
have increased to R2=0.47 (not shown). In contrast, the gene thera-
py treatment in Gunn rats yields a clear correlation between BDG inTable 2
Glucuronidation activity rates, in pmol/mg protein/min toward bilirubin, ezetimibe, 17α-eth
rats. The doses of scAAV were either high (h=1×1012 gc/kg), medium (m=3×1011 gc/k
serum bilirubin compared to the level in untreated Gunn rats. det, detectable; ND, not don
Gender Dose Correction Bilirubin
M h 88% 729.3±6.3
M h 78% 342.3±4.3
M h 93% 709.2±1.8
M h 88% 666.6±3.7
M m 75% 324.6±2.4
M m 80% 331.2±1.9
M m 68% det
M m 68% 328.9±1.9
M m 65% det
M m 70% det
M l 49% det
M l 55% det
M l 49% det
M l 42% det
F m 41% det
F m 55% det
F m 65% 260.7±2.6
F m 79% 274.2±2.1
M ctrl NA 0
M ctrl NA 0
M ctrl NA ND
M ctrl NA ND
F ctrl NA 0
F ctrl NA 0
F ctrl NA 0
F ctrl NA 0bile and the serum bilirubin levels (Fig. 2B). This indicates that bile
analyses to determine BDG presence before and after the treatment
in individual patients might be a reliable parameter for restored
UGT1A1 activity.
7.3. The effect of UGT1A1 gene therapy in Gunn rats on the in vitro
glucuronidation activity of liver microsomes toward bilirubin, estradiol,
ethinylestradiol and ezetimibe
A comparison of bilirubin glucuronidation activity in liver micro-
somes from all the Gunn rats that were included in this study rev-
ealed a good correlation between the different levels of the gene
therapy treatment, high, medium, low and control (untreated), to
the rate of bilirubin glucuronidation (Table 2). Moreover, bilirubin
glucuronidation activity in livers from male rats treated even with
the lowest virus dose was detectable, even if too low to quantify,
and resulted in a signiﬁcant (49±5%) reduction of the serum
UCB level (Table 2). In the medium dose cohort, the bilirubin
glucuronidation activity of the treated Gunn rats liver microsomes
was higher. In half of the male samples and half of the female sam-
ples of the middle dose group it was quantiﬁed (Table 2). These rats
were injected with a dose of 3×10e11 gc/kg of scAAV, a treatment
that provided a reduction of 72±6% in the serum UCB in males
and 60±16% in females (Table 2). Such a magnitude of serum UCB
reduction would have been signiﬁcant and therapeutic for human
CN I patients. The highest bilirubin glucuronidation activity was
found in livers from rats that were treated with the highest virus
dose (only male rats were included in this group) and resulted in a
serum UCB decrease of 87±6% (Table 2).
Since we have concluded that BDG in bile is not the most suitable
(neither patient-friendly) bio marker for the gene therapy treatment
we are developing for CN I patients, we have searched for other pos-
sibilities. The goal was to ﬁnd a nontoxic substrate for UGT1A1 that is
as selective as possible for hepatic UGT1A1. To this end, we have test-
ed the glucuronidation of estradiol, ethinylestradiol and ezetimibe by
the different samples of Gunn rat liver microsomes. None of these
three compounds was as selective for UGT1A1 as bilirubin. Nonethe-
less, the results revealed that ezetimibe may be a suitable biomarker,inylestradiol and 17β-estradiol in liver microsomes of scAAV-treated and control Gunn
g), or low (l=1×1011 gc/kg) or none (ctrl). Correction (%) refers to the reduction of
e; NA, not applicable.
Ezetimibe 17α-Ethinylestradiol 17β-Estradiol
55.9±4.9 60.0 1091.4
45.3±3.1 41.2 910.0
74.9±12.3 84.8 1153.3
47.7±4.1 62.9 953.8
det 36.5 1048.3
45.9±1.4 46.0 1123.3
53.8±2.3 40.2 883.3
46.6±7.5 37.8 1026.2
47.4±1.4 39.9 1116.1
42.2±4.6 40.0 1120.9
ND ND ND
ND ND ND
ND ND ND
ND ND ND
55.5±2.4 75.4 1118.9
48.1±4.0 63.5 1128.3
62.8±8.7 61.2 933.7
64.1±4.2 74.3 987.8
det 35.5 1032.8
0 40.0 533.3
0 ND ND
0 ND ND
68.3±4.7 49.5 1252.8
det 58.4 1172.7
63.5±16.5 62.3 1086.6
55.4±3.1 57.4 1233.1
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Fig. 3. Ezetimibe and ezetimibe glucuronide detection in plasma from untreated con-
trol and scAAV treated Gunn rats. (A) HPLC proﬁle of a control Gunn rat prior to
ezetimibe injection. (B) HPLC proﬁle of an scAAV treated Gunn rat prior to ezetimibe
injection. (C) HPLC proﬁle of a control (untreated) Gunn rat 20 min after ezetimibe in-
jection. (D) HPLC proﬁle of a treated Gunn rat 20 min after ezetimibe injection. The ar-
rows in the inserts indicate the position of the ezetimibe glucuronide peak as
detectable after 20 min and its integration.
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ezetimibe was detected in livers of untreated male rats, while in all
but one of the livers from animals treated with the medium or high
dose of gene therapy vector glucuronidation of this drug was clearly
detectable. However, in liver of untreated female rats, a signiﬁcant
background activity towards this compound was detected, suggesting
that it may be less suitable as a marker for restored UGT1A1 activity
in that gender. In the cases of estradiol and ethinylestradiol, the
glucuronidation activity in liver microsomes from control, (untreated)
rats, was in the same range as in microsomes from rats that were
treated with the medium and high virus infections (Table 2, note that
the liver microsomes from male rats that were treated with the low
dose were not analyzed in the assayed with ezetimibe, ethinylestradiol
and estradiol). Based on these results (Table 2) only ezetimibe was
used for the subsequent in vivo analyses.
7.4. Testing ezetimibe as a marker for UGT1A1 activity in Gunn rats in
vivo
Ezetimibe (2 mg/kg) was injected in the peritoneum and blood
was sampled, using heparin tubes, before the injection and at differ-
ent time intervals following it. Ezetimibe and ezetimibe glucuronide
concentrations in the plasma, following cells sedimentation by centri-
fugation, was determined by HPLC. Fig. 3A and C shows plasma HPLC
proﬁles from a control rat, either before ezetimibe injection (Fig. 3A),
or 20 min post injection (Fig. 3C). Ezetimibe glucuronide was eluted,
under the used chromatography conditions (see Methods for details),
at r.t. of about 12.2 min (insets in Fig. 3A–D), while the parent com-
pound, ezetimibe, was eluted at r.t. of about 17.2 min. The results
demonstrate that although a low level of ezetimibe glucuronide was
observed 20 min past injection even in control rats (Fig. 3C), the ac-
tivity was signiﬁcantly higher in scAAV-treated rats (Fig. 3D). The
ratio between ezetimibe glucuronide and unconjugated ezetimibe in
serum, as a function of time after injection, between a treated and a
control rat, is presented in Fig. 4A. This ratio was much higher in
the treated animals. Since ezetimibe and its glucuronide can be
reliably quantiﬁed at 20 min post injection in both treated and
untreated control Gunn rats, the ratio between the two compounds
at that time point was chosen as a measure for restored UGT1A1
activity. Subsequently, the serum concentrations of ezetimibe and
its glucuronide (at 20 min post i.p. injection) was used to determine
the correlation between the in vivo ezetimibe glucuronidation activ-
ity and the degree of serum bilirubin (UCB) correction, namely UCB
reduction that was achieved by scAAV-mediated gene therapy
(Fig. 4B and C). The correlation between these parameters was
observed in both male and female rats in these in vivo experiments.
This indicates that the formation of ezetimibe glucuronide upon
intra peritoneal scAAV injection may serve as a suitable serum
marker for the correction of hepatic UGT1A1 activity by gene
therapy.
8. Discussion
Severe unconjugated hyperbilirubinemia (the accumulation of
unconjugated bilirubin), called Crigler-Najar syndrome type I, or CN
I, is a rare inherited disease that is caused by different mutations
that fully or largely inactivate UGT1A1, the central enzyme in hepatic
bilirubin conjugation [2]. Presently, the only effective treatment for
CN I is a life-long phototherapy for 8–12 h each day [7]. We have
been interested in developing alternative and better therapies for
CN I and the recent success in gene therapy of hemophilia B through
factor IX expression, demonstrating the clinical potential of scAAV-
8 mediated liver directed gene therapy [1], raised the possibility
that restoring hepatic UGT1A1 activity using this viral delivery sys-
tem could be used to treat CN I patients, too.
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Fig. 4. Glucuronidation of ezetimibe in vivo correlates with correction in serum biliru-
bin in gene therapy treated Gunn rats. (A) The ratio of ezetimibe glucuronide to
ezetimibe at different times after injection in an untreated control (solid line, ▲) and
a Gunn rat treated with scAAV (dashed line, ♦). (B) The correlation between the
ratio of ezetimibe glucuronide to ezetimibe at 20 min after injection and the degree
of serum bilirubin correction in male Gunn rats. (C) The correlation between the
ratio of ezetimibe glucuronide to ezetimibe at 20 min after injection and the degree
of serum bilirubin correction in female Gunn rats.
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to test the treatment's efﬁcacy and this requirement also holds for
CN I. Since CN I is a rare syndrome, we think that the best way to
overcome the hurdle of too few patients for different control and
treatment groups to demonstrate efﬁcacy is to replace it in this case
with the characterization of the pathophysiology of each individual
patient before and after treatment, separately. In doing so, one ﬁrst
examines the serum UCB level, since very high UCB is the hallmark
of the disease and this data, since birth, is available at the treating
clinic or hospital. But since the serum UCB level is affected by the in-
tensity of the daily phototherapy and as long as the efﬁcacy of gene
therapy has not been clearly demonstrated, phototherapy must con-
tinue, the serum UCB level cannot serve as a biomarker. Hence,
there is a clear need for another biomarker and this need is the
starting point for the current study.
In searching for possible biomarkers for gene therapy for CN I we
have turned to exogenous UGT1A1 substrates. Several of them that
are rather highly selective for UGT1A1 and are not expected to be af-
fected by phototherapy have been identiﬁed [23,24]. Of these sub-
strates, etoposide may be the most selective for UGT1A1 (after
bilirubin), but it carries a considerable risk of toxicity, especially for
CN I patients. Therefore, we have examined estradiol and eth-
inylestradiol as potential markers for UGT1A1 activity in the liver
[15,20,25]. In vitro analyses, however, demonstrated no signiﬁcant
differences in the glucuronidation activity toward either estradiol or
ethinylestradiol between livers of control and treated Gunn rats
(Table 2), suggesting that one or more hepatic rat UGTs of subfamily
2B can catalyze these reactions at relatively high rates. On the other
hand, the results with the third exogenous UGT1A1 substrate that
we have tested, ezetimibe, were more promising, at least with male
rats (Table 2). The ezetimibe glucuronidation rates in liver micro-
somes of male control Gunn rats were very low, while in medium
and high doses treated rats (the low dose rats were not examined
with any of the exogenous substrates), the rates of ezetimibe
glucuronidation were clearly higher (Table 2). These ﬁndings are
also in agreement with the previously reported major role of UGT1A
in ezetimibe glucuronidation [16] and with the reduced ezetimibe
metabolism in Gunn rats that was reported by Yamamoto et al. [19].
The reported role of the human UGT1A3 in ezetimibe
glucuronidation, in addition to UGT1A1 [16], might suggest that
ezetimibe is only a suitable marker for CN patients with a mutation
in exons 2–5 (the shared exons) of UGT1A1, but not in exon 1
[2,26]. On the other hand, the hepatic expression level of UGT1A3 is
much lower than that of UGT1A1 [27,28], so it is expected that
UGT1A3 will not play a signiﬁcant role in in vivo ezetimibe
glucuronidation in humans. In any case, in our patient group, 9 of
the 12 potential candidates for gene therapy, those that need daily
phototherapy, have mutations in the shared exons of UGT subfamily
1A (Table 1 and [17]) and therefore lack UGT1A3 activity. In any
case, to be on the safe side, future studies on the suitability of
ezetimibe as a biomarker for gene therapy in human CN I patients
should be evaluated separately for patients who have the inactivating
UGT1A1 mutation(s) in solely in exon 1 or in the promoter region of
the gene.
One surprising ﬁnding of this study is the relatively high ezetimibe
glucuronidation activity in the liver of (untreated) female control
Gunn rats. The relatively high background in these controls may ex-
plain the lack of clear effects of the gene therapy treatment on the
ezetimibe glucuronidation in this group of animals (Table 2). It may
be noted here that the previous study on ezetimibe glucuronidation
in Gunn rats [19] did not include female rats at all and this is probably
the reason that this sex dependence was not detected earlier. Since
both Gunn rat genders lack all UGT1A enzymes, the increased
ezetimibe glucuronidation by one of the UGT2B enzymes that is
expressed at higher level in the rat female than rat male liver is prob-
ably responsible for this. In man UGT2B15 and UGT2B7 have been
1229PS.. Montenegro-Miranda et al. / Biochimica et Biophysica Acta 1822 (2012) 1223–1229reported to glucuronidate this compound [16]. Given the up regula-
tion of UGT2B15 by estrogen, it might be suggested that the equiva-
lent of UGT2B15 in the rat is responsible for the increased ezetimibe
glucuronidation activity observed in liver microsomes from female
Gunn rats [29]. Our results highlight the importance of using both
sex animals in preclinical tests, at least when the drugs are intended
for both male and female patients. Nevertheless, it is important to
point out that there are many differences in the substrate speciﬁcity
of human UGTs in comparison to different animals’ UGT enzymes
[30] and at this stage we should not draw the conclusion that in
humans the gender differences in ezetimibe glucuronidation in the
absence of an active UGT1A1 will be similar to that in Gunn rats. It
may also be added that although the results from the in vitro assays
with rat liver microsomes demonstrated a large difference between
control male to female sample in ezetimibe glucuronidation rates,
the in vivo assays revealed that also in female rats there is a clear dif-
ference in ezetimibe glucuronidation between treated to untreated
rats, at least when the blood sample is taken 20 min post injection
(Fig. 4C). These results suggest that, regardless the results with liver
microsomes, ezetimibe can serve as a suitable biomarker also in fe-
male Gunn rats.
In conclusion, we have shown in this study that, in Gunn rats, the
determination of BDG presence in the bile before and after gene ther-
apy is a sensitive method to detect restored UGT1A1 activity. Howev-
er, since this invasive method is not a viable option for frequent
monitoring in human CN I patients, we have examined the potential
of using three exogenous substrates of hepatic UGT1A1, as bio-
markers for gene therapy treatment of CN I patients. At least in this
animal model of the disease, the cholesterol lowering drug ezetimibe
appeared suitable for this role. After additional dosing and safety
studies, it may be suitable, as a surrogate parameter, to demonstrate
the efﬁcacy of scAAV‐mediated liver directed gene therapy also in
Crigler-Najjar patients.
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